Biogen (BIIB) – Research Analysts’ Recent Ratings Changes

Biogen (NASDAQ: BIIB) recently received a number of ratings updates from brokerages and research firms:

• 12/20/2024 – Biogen was upgraded by analysts at StockNews.com from a “buy” rating to a “strong-buy” rating.
• 12/20/2024 – Biogen was downgraded by analysts at BMO Capital Markets from an “outperform” rating to a “market perform” rating. They now have a $164.00 price target on the stock, down previously from $230.00.
• 12/16/2024 – Biogen was downgraded by analysts at Stifel Nicolaus from a “buy” rating to a “hold” rating. They now have a $175.00 price target on the stock.
• 12/11/2024 – Biogen was downgraded by analysts at StockNews.com from a “strong-buy” rating to a “buy” rating.
• 12/10/2024 – Biogen had its “neutral” rating reaffirmed by analysts at Bank of America Co.. They now have a $178.00 price target on the stock.
• 12/9/2024 – Biogen was downgraded by analysts at Jefferies Financial Group Inc. from a “buy” rating to a “hold” rating. They now have a $180.00 price target on the stock, down previously from $250.00.
• 11/21/2024 – Biogen had its price target lowered by analysts at Mizuho from $251.00 to $207.00. They now have an “outperform” rating on the stock.
• 11/18/2024 – Biogen was downgraded by analysts at Needham & Company LLC from a “buy” rating to a “hold” rating. They now have a $270.00 price target on the stock.
• 11/15/2024 – Biogen is now covered by analysts at Wolfe Research. They set a “peer perform” rating on the stock.
• 11/15/2024 – Biogen had its price target raised by analysts at Robert W. Baird from $294.00 to $300.00. They now have an “outperform” rating on the stock.
• 11/14/2024 – Biogen is now covered by analysts at Citigroup Inc.. They set a “neutral” rating and a $190.00 price target on the stock.
• 11/13/2024 – Biogen was upgraded by analysts at Citigroup Inc. to a “hold” rating.
• 11/4/2024 – Biogen had its price target lowered by analysts at JPMorgan Chase & Co. from $220.00 to $210.00. They now have a “neutral” rating on the stock.
• 10/31/2024 – Biogen had its price target lowered by analysts at Oppenheimer Holdings Inc. from $270.00 to $255.00. They now have an “outperform” rating on the stock.
• 10/31/2024 – Biogen had its price target lowered by analysts at Barclays PLC from $190.00 to $180.00. They now have an “equal weight” rating on the stock.
• 10/31/2024 – Biogen was downgraded by analysts at Morgan Stanley from an “overweight” rating to an “equal weight” rating. They now have a $204.00 price target on the stock, down previously from $285.00.
• 10/31/2024 – Biogen had its price target lowered by analysts at TD Cowen from $300.00 to $275.00. They now have a “buy” rating on the stock.
• 10/31/2024 – Biogen had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $300.00 price target on the stock.
• 10/30/2024 – Biogen had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $270.00 price target on the stock.

Biogen Trading Down 0.6 %

Shares of NASDAQ:BIIB opened at $146.47 on Monday. The business’s 50 day simple moving average is $167.48 and its 200 day simple moving average is $195.60. Biogen Inc. has a 1 year low of $145.07 and a 1 year high of $268.30. The company has a debt-to-equity ratio of 0.28, a current ratio of 1.26 and a quick ratio of 0.80. The company has a market capitalization of $21.34 billion, a P/E ratio of 13.23, a P/E/G ratio of 1.83 and a beta of -0.08.

Biogen (NASDAQ:BIIB) last issued its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $4.08 EPS for the quarter, topping analysts’ consensus estimates of $3.77 by $0.31. Biogen had a return on equity of 14.98% and a net margin of 16.81%. The company had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.43 billion. During the same quarter last year, the business earned $4.36 earnings per share. Biogen’s revenue was down 2.5% on a year-over-year basis. On average, research analysts anticipate that Biogen Inc. will post 16.43 EPS for the current fiscal year.

Institutional Investors Weigh In On Biogen

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. Itau Unibanco Holding S.A. acquired a new position in shares of Biogen during the 2nd quarter worth $33,000. Ashton Thomas Securities LLC bought a new position in Biogen in the third quarter valued at about $33,000. Venturi Wealth Management LLC boosted its stake in shares of Biogen by 73.8% during the third quarter. Venturi Wealth Management LLC now owns 219 shares of the biotechnology company’s stock valued at $42,000 after purchasing an additional 93 shares in the last quarter. McClarren Financial Advisors Inc. grew its holdings in shares of Biogen by 11,450.0% during the second quarter. McClarren Financial Advisors Inc. now owns 231 shares of the biotechnology company’s stock worth $54,000 after purchasing an additional 229 shares during the last quarter. Finally, UMB Bank n.a. increased its stake in shares of Biogen by 139.8% in the second quarter. UMB Bank n.a. now owns 247 shares of the biotechnology company’s stock valued at $57,000 after buying an additional 144 shares during the period. 87.93% of the stock is currently owned by institutional investors.

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.